
In the CodeBreaK 200 trial, sotorasib outperformed docetaxel in treating KRAS G12C-mutated advanced NSCLC, demonstrating better quality of life (QOL) outcomes. Patients on sotorasib experienced fewer and less severe symptoms, and QOL remained stable, unlike with docetaxel, where QOL declined. These findings highlight sotorasib as a more tolerable treatment option for patients with advanced NSCLC who have received prior therapy.
Like
Save
Share